LIFE: Lifecare newsletter

Bergen, Norway 12 May 2023 

Lifecare's latest updates include information of the recently finalized clinical
study and the presentation of study results on the upcoming American Diabetes
Association Congress in San Diego, the company's Q1 2023 report, ISO 9001
certification of Lifecare Laboratory and the progress for our planned
manufacturing site in Mainz, Germany.  

Read more in Lifecare's newsletter on this link: 

https://us20.campaign-archive.com/?u=f0eeef8df637c6b4d457c5ead&id=a6db52caaf


ABOUT LIFECARE
Lifecare AS is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on
the sensor body for read-out of pressure variations. LifecareŽs sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the human
body. 

Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no,
+47 40 05 90 40 

This stock exchange announcement was published by Joacim Holter, CEO at Lifecare
AS, on 12 May 2023 at 11:43 CET.